Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease

Clinical Neuropharmacology

Volumn 21, Issue 3, 1998, Pages 152-158

  Van Laar, T ^a   Van der Geest, R ^b,c   Danhof, M ^b   Bodde H E ^b   Goossens, P H ^a   Roos, R A C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Apomorphine; Minimal effective concentration; Minimal toxic concentration; Onset offset; Parkinson's disease; Pharmacodynamics

Indexed keywords

APOMORPHINE; DOMPERIDONE;

ADULT; AGED; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG EFFICACY; DYSKINESIA; FEMALE; HALLUCINATION; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; SEDATION; VERTIGO;

EID: 0031840211     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. DiChiara G, Gessa GL. Pharmacology and neurochemistry of apomorphine. Adv Pharmacol Chemother 1978;15:87-159.
2. Baidessarini RJ, Arana GW, Kula NS, Campbell A, Harding M. Preclinical studies of the pharmacology of aporphines. In: Corsini GU, Gessa GL, eds. Apomorphine and other dopaminomimetics: basic pharmacology, vol 1. New York: Raven Press, 1981:219-28.
3. Stibe CMH, Lees AJ, Kempster PM, Stem GM. Subcutaneous apomorphine in parkinsonian on-off fluctuations. Lancet 1988;i:403-6.
4. Van Laar T, Jansen ENH, Essink AWG, Neef C. Intranasal apomorphine in parkinsonian on-off fluctuations. Arch Neural 1992;49: 482-4.
5. Van Laar T, Jansen ENH, Essink AWG. Rectal apomorphine: a new treatment modality in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:737-8.
6. Van Laar T, Neef C. Danhof M, Roon KI, Roos RAC. A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease. Mov Disord 1996;11:633-8.
7. Gancher ST, Woodward WR, Boucher B, Nutt JG. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989;26: 232-8.
8. Van der Geest R, Van Laar T, Kruger PP, et al. Pharmacokinetics, enantiomer interconversion and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. J Clin Neuropharmacol 1998;21:159-168.
9. Rascol OJ, Montastruc JL. Cardiovascular effects of apomorphine in humans: evidence for peripheral mechanisms. Clin Neuropharmacol 1986;9:566-9.
10. Van der Geest R, Kruger P, Gubbens-Stibbe JM, Van Laar T, Boddé, Danhof M. High performance liquid Chromatographie analysis of (R+)-apomorphine and its metabolites in plasma and urine of parkinsonian patients. J Chromotogr B Biomed Appl 1997;702:131-141.
11. Cannon JG, Smith RV, Modiri A, et al. Central acting emetics. V. Preparation and pharmacology of isoapocodeine, in vitro enzymatic methylation of apomorphine. J Med Chem 1972;15:273-6.
12. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II. Ann Neurol 1988;24:372-8.
13. Contin M, Riva R, Marinelli P, Cortelli P, Albani F, Baruzzi A. Pharmacodynamic modelling of oral L-dopa: clinical application in Parkinson's disease. Neurology 1993;43:367-71.
14. Champion MC. Domperidone: a mini review. Gen Pharmacol 1988; 19:499-505.
15. Pollak P, Mallaret M, Gaio JM, Hommel M, Perret J. Blood pressure effects of apomorphine and domperidone in Parkinsonism. In: Yahr MD, Bergmann KJ, eds. Advances in neurology. New York: Raven Press, 1986:263-6.
16. Parkes JD. Domperidone and Parkinson's disease: a review. Clin Neuropharmacol 1986;9:517-32.
17. Bredberg E, Paalzow LK. Effects of apomorphine on heart rate during simultaneous administration of sulpiride: a challenge of the composed concentration-effect model. J Pharmacol Exp Ther 1991;258:1055-60.